Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05867914 · ClinicalTrials.gov registry record · NA
Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD
A NA study of Lung Diseases, Interstitial and Hypertension, Pulmonary, sponsored by Third Pole Therapeutics.
- Active
- Registry status
- NA
- Development phase
- 5
- Enrollment target
- 3
- Study locations
NCT05867914 is a NA study of Lung Diseases, Interstitial and Hypertension, Pulmonary that is active but no longer recruiting, run by Third Pole Therapeutics. The registered enrollment target is 5 participants, below the 12,508-participant average among 10 other Lung Diseases, Interstitial trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05867914, a NA study of Lung Diseases, Interstitial and Hypertension, Pulmonary, is active but no longer recruiting, sponsored by Third Pole Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
- 3
- Study locations
Study Summary
A trial to evaluate the safety, tolerability, and functionality of 3P-100, in subjects with Pulmonary Hypertension (PH) accompanying Interstitial Lung Disease (ILD), PH-ILD
Conditions Studied
Interventions
- DEVICE Inhaled Nitric Oxide (iNO)
Study Locations (3)
Florida
- TGH/USF Center for Advanced Lung Disease and Lung Transplant - Tampa
Ohio
- University of Cincinnati - Cincinnati
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-12-04 |
| Est. Completion | 2024-03-29 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05867914
The ClinicalTrials.gov registry entry for NCT05867914 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,508-participant average among 10 other Lung Diseases, Interstitial trials with a reported enrollment target (100% lower). The listed sponsor is Third Pole Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lung Diseases, Interstitial appearing as the primary indexed condition, and to 1 intervention - of which Inhaled Nitric Oxide (iNO) is the first listed.
NCT05867914 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Ohio, South Carolina.
Frequently Asked Questions
What is clinical trial NCT05867914 about?
NCT05867914 is a clinical study titled "Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD". A trial to evaluate the safety, tolerability, and functionality of 3P-100, in subjects with Pulmonary Hypertension (PH) accompanying Interstitial Lung Disease (ILD), PH-ILD
What is the current status of trial NCT05867914?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 5 participants. The study started on 2023-12-04. Estimated completion is 2024-03-29.
What conditions does trial NCT05867914 study?
This clinical trial studies the following conditions: Lung Diseases, Interstitial, Hypertension, Pulmonary.
What interventions are being tested in trial NCT05867914?
The interventions under investigation include: Inhaled Nitric Oxide (iNO) (DEVICE).
Who is sponsoring clinical trial NCT05867914?
This trial is sponsored by Third Pole Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05867914 being conducted?
This trial has 3 study locations across Florida, Ohio, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Diseases, Interstitial
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Physical Activity and Quality of Life in Fibrotic Lung Diseases After Initiating Anti-fibrotic Therapy and Pulmonary Rehabilitation
RECRUITING · NA
-
Oxygen Savings With Administered Oxygen and High Flow Ambient Air At Rest
COMPLETED · NA
-
Project to Improve Communication About Serious Illness--Hospital Study: Pragmatic Trial (Trial 1)
COMPLETED · NA
-
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
RECRUITING · Phase 3
-
Dorothy P. and Richard P. Simmons Center for ILD Research Registry
RECRUITING
-
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.